金吾财讯 | 赛诺菲安万特(SNY)盘前股价上扬，暂升0.51%，报47.75美元。公司宣布，普乐司兰钠注射液（商品名：瑞达普）正式在中国国内获批，用于在饮食控制基础上降低家族性乳糜微粒血症综合征（FCS）成人患者的甘油三酯水平。该药是全球首个作用于创新靶点APOC3（载脂蛋白C-III） mRNA的小干扰RNA药物。
金吾财讯 | 赛诺菲安万特(SNY)盘前股价上扬，暂升0.51%，报47.75美元。公司宣布，普乐司兰钠注射液（商品名：瑞达普）正式在中国国内获批，用于在饮食控制基础上降低家族性乳糜微粒血症综合征（FCS）成人患者的甘油三酯水平。该药是全球首个作用于创新靶点APOC3（载脂蛋白C-III） mRNA的小干扰RNA药物。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.